129 related articles for article (PubMed ID: 18234315)
1. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia.
Simon D; Salemi S; Yousefi S; Simon HU
J Allergy Clin Immunol; 2008 Apr; 121(4):1054-6. PubMed ID: 18234315
[No Abstract] [Full Text] [Related]
2. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene.
Thuny C; Gaudy-Marqueste C; Nicol I; Gabert J; Costello R; Grob JJ; Richard MA
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):234-5. PubMed ID: 19686260
[No Abstract] [Full Text] [Related]
3. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
4. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
[No Abstract] [Full Text] [Related]
5. [Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan].
Sada A; Matsui T
Rinsho Ketsueki; 2010 Jul; 51(7):515-25. PubMed ID: 20693771
[No Abstract] [Full Text] [Related]
6. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
[TBL] [Abstract][Full Text] [Related]
7. [Spontaneous pneumothorax, an unusual manifestation of imatinib-resistant chronic eosinophilic leukemia: an autopsy study].
Fujimi A; Kanisawa Y; Tanaka S; Okuda T; Sato Y; Doi T; Ohta H; Iwasaki S; Ishizu A; Huang Y
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):862-5. PubMed ID: 19432135
[No Abstract] [Full Text] [Related]
8. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
9. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody.
Wagner LA; Speckart S; Cutter B; Gleich GJ
J Allergy Clin Immunol; 2009 Jun; 123(6):1407-8. PubMed ID: 19342084
[No Abstract] [Full Text] [Related]
10. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
11. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib.
Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE
Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486
[No Abstract] [Full Text] [Related]
12. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
[No Abstract] [Full Text] [Related]
13. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Helbig G; Stella-Hołowiecka B; Hołowiecki J
Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
[No Abstract] [Full Text] [Related]
14. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Metzgeroth G; Erben P; Martin H; Mousset S; Teichmann M; Walz C; Klippstein T; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2012 Jan; 26(1):162-4. PubMed ID: 21818111
[No Abstract] [Full Text] [Related]
15. Chronic eosinophilic leukemia presenting with mouth and penile ulcers.
Najera JE; Harn L
Am J Med; 2012 Aug; 125(8):e5-6. PubMed ID: 22681908
[No Abstract] [Full Text] [Related]
16. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
[No Abstract] [Full Text] [Related]
17. [Chronic eosinophilic leukemia].
Ouakaa-Kchaou A; Belhadj N; Ennaifer R; Hefaiedh R; Elloumi H; Gargouri D; Ghorbel A
Tunis Med; 2009 Apr; 87(4):303. PubMed ID: 19835296
[No Abstract] [Full Text] [Related]
18. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Seferyńska I; Raźny M; Rodzaj M; Żuk E; Kyrcz-Krzemień S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):967-9. PubMed ID: 21327932
[No Abstract] [Full Text] [Related]
19. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
20. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate.
Tashiro H; Shirasaki R; Noguchi M; Gotoh M; Kawasugi K; Shirafuji N
Int J Hematol; 2006 Jun; 83(5):433-8. PubMed ID: 16787876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
